中恆集團(600252.SH):收到注射用甲潑尼龍琥珀酸鈉的藥品註冊證書
格隆匯 8 月 13日丨中恆集團(600252.SH)公佈,公司的控股子公司重慶萊美藥業股份有限公司(“萊美藥業”)近日收到國家藥品監督管理局核准簽發的注射用甲潑尼龍琥珀酸鈉《藥品註冊證書》。
注射用甲潑尼龍琥珀酸鈉是一種人工合成的糖皮質激素,由現隸屬於輝瑞制藥的法瑪西亞普強公司(PHARMACIA AND UPJOHN)研發,於1959年在美國首次上市,商品名為甲強龍(SOLU-MEDROL)。主要用於抗炎治療(如風濕性疾病、膠原疾病、皮膚疾病等)、免疫抑制治療(器官移植)、血液疾病(獲得性溶血性貧血、成人自發性血小板減少性紫癜、成人繼髮型血小板減少等)、腫瘤(成人白血病和淋巴瘤、兒童急性白血病的姑息治療)、休克治療、內分泌失調。甲潑尼龍琥珀酸鈉極易溶於水,供靜脈或肌肉注射用,在血漿中迅速水解,以遊離甲潑尼龍的形式發揮藥理作用。與潑尼鬆龍相比,除了具有糖皮質激素的藥理作用外,有更強的抗炎作用和較弱的水、鈉瀦留作用。
米內網數據顯示注射用甲潑尼龍琥珀酸鈉2017年、2018年、2019年在中國的銷售額分別為10.55億、11.67億、12.19億,近三年銷售額均穩步增長。
截至目前,萊美藥業對該產品累計已投入研發費用736.06萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.